64230-60-0

Basic information

• Product Name: 2-Bromo-3-methylfuran
• Synonyms: 2-Bromo-3-methylfuran
• CAS NO: 64230-60-0
• Molecular Formula: C5H5BrO
• Molecular Weight: 161
• Product Categories: Furans
• Mol File: 64230-60-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 133.51°C at 760 mmHg
• Flash Point: 34.546°C
• Appearance: /
• Density: 1.538g/cm³
• Vapor Pressure: 10.389mmHg at 25°C
• Refractive Index: 1.505
• CAS DataBase Reference: 2-Bromo-3-methylfuran(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-3-methylfuran(64230-60-0)
• EPA Substance Registry System: 2-Bromo-3-methylfuran(64230-60-0)

Safety Data

• Hazardous Substances Data: 64230-60-0(Hazardous Substances Data)

Usage

General Description

2-Bromo-3-methylfuran is a chemical compound with the molecular formula C5H5BrO. It is a brominated derivative of 3-methylfuran, which is a heterocyclic compound containing a furan ring with a methyl group and a bromine atom attached to it. 2-Bromo-3-methylfuran is commonly used as a building block or intermediate in the synthesis of various organic compounds, including pharmaceuticals and agrochemicals. It is also utilized in the production of flavors and fragrances due to its unique aromatic properties. Additionally, it has potential applications in the field of materials science, such as in the development of polymers and other advanced materials. Due to its reactivity and potential health hazards, proper safety precautions should be taken when handling 2-Bromo-3-methylfuran.

InChI:InChI=1/C5H5BrO/c1-4-2-3-7-5(4)6/h2-3H,1H3

Upstream product

• 930-27-8 3-methylfuran 
• 128-08-5 N-Bromosuccinimide 

Downstream Products

• 39007-94-8 longifolin 

Relevant articles and documents

(PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with ΤGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.

New aspects in the synthesis of mono- and dialkylfurans

3-substituted furan systems can be obtained by alkylation of 3-lithium furans with various electrophiles in the presence of hexamethylphosphoric acid triamide in good yields. The 2- or 5-position of 3-methyl furan is blocked with high regio selectivity by silylation. After metalation and alkylation of the remaining free α-position and subsequent desilylation the 2,3- and 2,4-disubstituted furans are obtained. These methods are used to synthesize the naturally occuring compounds ursinanolide (2) and longifolin (4).